Novo Nordisk Reports Positive Trial Results for Sickle Cell Disease Drug

Novo Nordisk (NVO) announced that its Phase 3 trial for etavopivat, an experimental therapy for sickle cell disease, met both co-primary endpoints. The company plans to seek regulatory approval for the drug in 2024.

By Dulan Lokuwithana, SA News Editor · Seeking Alpha · April 20, 2026, 10:52 UTC

Novo Nordisk Reports Positive Trial Results for Sickle Cell Disease Drug

Tickers: $NVO

Topics: clinical trials drug approval pharmaceuticals sickle cell disease

Read the full article at Seeking Alpha

More World news

CorMedix Announces Acquisition of Heron Therapeutics Assets to Drive Revenue Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Tetra Tech Forecasts FY 2027 Revenue Between $4.425B and $4.625B Amid Backlog Growth Seeking Alpha · November 12, 2026, 19:20 UTC
Donald Trump Jr. Steps Down from Kalshi Advisory Role Due to Conflict of Interest CNBC · November 12, 2026, 19:14 UTC
Centalion Americas Refinances and Upsizes Credit Facility to $3.5 Billion PR Newswire · November 12, 2026, 19:15 UTC
Nvidia Faces Leadership Transition as Jensen Huang Resigns Amid Investigation Seeking Alpha · November 12, 2026, 18:30 UTC
SOLV Energy Reports Record Q3 2026 Results and Raises Full-Year Guidance Motley Fool · November 12, 2026, 19:09 UTC
Clear Secure Reports Strong Q3 Earnings and Raises Full Year Guidance Amid Expansion into Identity Verification CNBC · November 12, 2026, 19:09 UTC
Nectar Launches AI Agent to Automate Influencer Discovery and Outreach TechCrunch · November 12, 2026, 19:11 UTC
Cohen & Company Appoints Daniel Cohen as CEO with $500 Million Revenue Target Seeking Alpha · November 12, 2026, 19:10 UTC
X-Energy Receives Early NRC Construction Permit and Anticipates Dow Investment Decision by 2027 Seeking Alpha · November 12, 2026, 19:10 UTC